Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Oshima, Megumi, Jardine, Meg J., Agarwal, Rajiv, Bakris, George, Cannon, Christopher P., Charytan, David M., de Zeeuw, Dick, Edwards, Robert, Greene, Tom, Levin, Adeera, Lim, Soo Kun, Mahaffey, Kenneth W., Neal, Bruce, Pollock, Carol, Rosenthal, Norman, Wheeler, David C., Zhang, Hong, Zinman, Bernard, Perkovic, Vlado, Heerspink, Hiddo J.L.·2021·Kidney International
DOI 10.1016/j.kint.2020.10.042

Cited by (167)

Items 101–167 of 167

  1. Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations
    Ioannis Boutsikos, Eleftherios T. Beltsios, Bastian Schmack, Ioannis N. Pantazopoulos, Dimitrios Chatzis · 2023 · Heart International
  2. Identification of risk factors associated with acute kidney injury in patients taking sodium‐glucose cotransporter‐2 inhibitors
    Christie Schumacher, Amanda Chorpash, Charlotte Bolch, Kellye Eagan, Sara Nimer, Elizabeth Van Dril · 2023 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  3. SGLT2 inhibitor: 2-way superstar in nephrology?
    Masaomi Nangaku · 2024 · Kidney International
  4. The Future of Chronic Kidney Disease Treatment: Combination Therapy (Polypill) or Biomarker-Guided Personalized Intervention?
    Sajjad Biglari, Harald Mischak, Joachim Beige, Agnieszka Latosińska, Justyna Siwy, Mirosław Banasik · 2025 · Biomolecules
  5. HbA1c and beyond
    Peter R Rossing · 2021 · Nephrology Dialysis Transplantation
  6. Acute Estimated Glomerular Filtration Rate Decline After Initiation of Therapies That Slow Kidney Disease Progression: Clinical Practice Implications
    David Z.I. Cherney, Radica Z. Alicic, Marc P. Bonaca · 2026 · Mayo Clinic Proceedings
  7. Gliflozines use in heart failure patients. Focus on renal actions and overview of clinical experience
    Edoardo Gronda, Massimo Iacoviello, Arduino Arduini, Manuela Benvenuto, Domenico Gabrielli, Mario Bonomini, Luigi Tavazzi · 2024 · European Journal of Internal Medicine
  8. Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index
    Peter R Rossing, Andreas L. Birkenfeld, Paola Fioretto, Janet B. McGill, Stefan D. Anker, Bertram Pitt, Katja Rohwedder, Andrea Viviana Scalise, Charlie A. B. Scott, Gerasimos S Filippatos et al. · 2025 · Clinical Journal of the American Society of Nephrology
  9. SGLT2 inhibition in chronic kidney disease: a preventive strategy against acute kidney injury at the same time?
    Sho Hasegawa, Masaomi Nangaku · 2022 · Kidney International
  10. Renal outcomes with sodium‐glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases
    Hiroaki Iijima, Maki Gouda, Hideaki Hida, Kazumi Mori‐Anai, Akiko Takahashi, Ryoichi Minai, Hideki Ninomiya, Yoshiyuki Saito, Atsushi Miyawaki, Jun Wada · 2024 · Diabetes Obesity and Metabolism
  11. Factors that lead to dialysis as the preferred treatment modality for patients with chronic kidney disease
    Anthony J. Bleyer · 2021 · Current Opinion in Nephrology & Hypertension
  12. Early reduction in albuminuria is associated with a steeper ‘dip’ in initial estimated glomerular filtration rate but favourable long‐term kidney outcomes in people with diabetes receiving sodium‐glucose cotransporter‐2 inhibitors
    Yi‐Wei Kao, Kun‐Chi Yen, Shao‐Wei Chen, Tze‐Fan Chao, Yi‐Hsin Chan · 2024 · Diabetes Obesity and Metabolism
  13. SGLT2 Inhibitors May Increase Creatinine Clearance: Data Mining Utilizing the FDA Adverse Event Report System Database and Pharmacokinetic Study with Rats
    Yuichi Uwai, Tomohiro Nabekura · 2025 · Pharmacology
  14. Effect of Initial eGFR and Albuminuria Changes on Clinical Outcomes in People With Diabetes Receiving SGLT2 Inhibitors
    Birdie Huang, Yi-Wei Kao, Kun‐Chi Yen, Shao‐Wei Chen, Tze‐Fan Chao, Yi‐Hsin Chan · 2025 · The Journal of Clinical Endocrinology & Metabolism
  15. Predictive Factors of Renal Function Decline in Patients with Type 2 Diabetes Treated with Canagliflozin in the Real-Wecan Study
    Juan José Gorgojo Martínez, Miguel Ángel Brito-Sanfiel, Teresa Antón-Bravo, Alba Galdón Sanz-Pastor, JAIME E.M. WONG-CRUZ, Manuel A. Gargallo Fernández · 2022 · Journal of Clinical Medicine
  16. Diabetic Nephropathy, Retinopathy, and Functional Hypogonadism in a Patient with MODY10: A Case Report
    Rossana Ruiz-Urbaez, Mariela Viviana Villagómez-Estrada, Carlos Alberto Reyes-Silva, Darlyng Patricia Quishpe Lopez, David Males, Jorge Salazar-Vega, Enrique Gea–Izquierdo · 2024 · Medicina
  17. Diabetic Chronic Kidney Disease in Type 2 Diabetes Mellitus (Albuminuric/Non-albuminuric)
    Stefanos K. Roumeliotis, Francesca Mallamaci, Carmine Zoccali · 2023 · Updates in hypertension and cardiovascular protection
  18. Emerging Role of Sodium–Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease
    Rey Isidto, Romina A. Danguilan, Oscar D. Naidas, Russell Villanueva, Mel-Hatra Arakama, Layla Marie Paraiso · 2023 · International Journal of Nephrology and Renovascular Disease
  19. SGLT2i and Deterioration of Kidney Function in Heart Failure
    Steven G. Coca · 2023 · Journal of the American College of Cardiology
  20. Initial change in fractional excretion of total protein after SGLT2 inhibitors predicts renal prognosis in patients with chronic kidney disease
    Hideaki Kuno, Go Kanzaki, Rina Oba, Hirokazu Marumoto, Saeko Hatanaka, Takaya Sasaki, Kotaro Haruhara, Kei Matsumoto, Kentaro Koike, Hiroyuki Ueda et al. · 2025 · Clinical Kidney Journal
  21. Initial Dip in Estimated Glomerular Filtration Rate After Dapagliflozin Affects Renal Function in Chronic Phase in Chronic Heart Failure
    Raisa Ogata, Takato Kotaki, Kozue Tanaka, Kyoko Higuchi, Natsumi Kumano, Kyoji Furukawa, Yoshihiro Fukumoto · 2025 · Journal of Clinical Medicine
  22. Combination therapy with mineralocorticoid receptor antagonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in chronic kidney disease: an updated meta-analysis of randomized controlled trials
    Shaikh Muhammad Daniyal, Hareem Ajaz, Minahil Riaz, Naveen Murad Khatoon, Zunaira Aftab, Habiba Tauqir Gondal, Isbah Gul, Mahwish Sarwar, Fizza Batool, Syeda Laiba Fahim et al. · 2025 · BMC Nephrology
  23. Impact of SGLT2 Inhibitors on Kidney Function Among People With HIV: A US Prospective Multisite Study
    Lara Haidar, Heidi M. Crane, Robin M. Nance, Malcolm Bray Doupe, Christine Leong, Laura P Bamford, Greer Burkholder, Edward R. Cachay, Katerina Christopoulos, Alexander Commanday et al. · 2026 · JAIDS Journal of Acquired Immune Deficiency Syndromes
  24. Estimated Glomerular Filtration Rate Change and Heart Failure Events With GLP ‐1 Receptor Agonists: A Meta‐Analysis and Meta‐Regression of Randomised Controlled Trials
    Masashi Hasebe, Hisashi Kamido, Chen‐Yang Su, Yamato Keidai, Daisuke Yabe, Satoshi Yoshiji · 2026 · Diabetes Obesity and Metabolism
  25. 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA)
    Kevin Damman, Jozine M. ter Maaten, Kaitlin J. Mayne, Davide Bolignano, Elizabeth M Brown, Bruno R. da Costa, Anna G. Dagre, Ron T. Gansevoort, Cristina Gavina, Andreas Goette et al. · 2026 · European Heart Journal
  26. Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial
    Satoshi Yamaguchi, Michio Shimabukuro, Atsushi Tanaka, Takumi Imai, Shinya Hiramitsu, Naohiko Takahashi, Toshiaki Kadokami, Masayoshi Ajioka, Makoto Suzuki, Koichi Node et al. · 2022 · Diabetes Obesity and Metabolism
  27. Sildenafil and Kidney Function in Heart Failure with Preserved Ejection Fraction
    Daniel L. Edmonston, Matthew A. Sparks, Sudarshan Rajagopal, Myles Selig Wolf · 2023 · Kidney360
  28. Erythrocytosis and thrombotic events in kidney transplant recipients prescribed a sodium glucose cotransport‐2 inhibitor
    Maia P. Gill, Marianna Leung, C. Luo, Catherine Cheung, Arielle Beauchesne, Doris Chang, James H. Lan, Olwyn Johnston · 2023 · Clinical Transplantation
  29. Renal outcomes after contrast exposure in patients with diabetes who use sodium–glucose cotransporter 2 inhibitors
    Chih‐Wei Chen, Fu-You Su, Pingping Wang, Ming‐Tsang Chuang, Yi Lin, Chih‐Chin Kao, Chun‐Yao Huang · 2023 · Postgraduate Medical Journal
  30. Updating and calibrating the Real‐World Progression In Diabetes (RAPIDS) model in a non‐Veterans Affairs population
    Anirban Basu, Felipe Montano‐Campos, Elbert S. Huang, Neda Laiteerapong, Douglas Barthold · 2024 · Diabetes Obesity and Metabolism
  31. The association between the eGFR slope and cardiorenal prognosis in patients with renoprotective treatments: A systematic review and meta‐analysis
    Shuzhen Bai, Chu Lin, Xiaoling Cai, Han Wu, Ruoyang Jiao, Suiyuan Hu, Fang Lv, Wenjia Yang, Linong Ji · 2024 · Journal of Evidence-Based Medicine
  32. Author's reply: Detailed Causality between Sodium-glucose Cotransporter 2 Inhibitor and Tubulointerstitial Nephritis
    Yusuke Konta, Eiichiro Saito, Koji Sato, Kyohei Furuta, Kenichiro Miyauchi, Akiko Furukawa, Hiroshi Sato, Tae Yamamoto · 2022 · Internal Medicine
  33. Sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction
    Jamie Falk, Jennifer Potter, Ricky D. Turgeon · 2021 · Canadian Family Physician
  34. Diabetic Kidney Disease: Increasing Hope with Transformative Therapies
    Sylvia E. Rosas, Samer Nasser · 2023 · Springer eBooks
  35. Mechanisms, Magnitude, and Consequence of Acute Estimated Glomerular Filtration Rate Change With Guideline-Directed Medical Therapy Initiation in Heart Failure
    Tariq Shafi, Shane A. Bobart · 2026 · The American Journal of Cardiology
  36. Real‐world risk factors and clinical implications of early estimated glomerular filtration rate decline after sodium‐glucose cotransporter‐2 inhibitor therapy
    Jangwook Lee, Dayoung Kang, Kyoung‐Ah Kim, Han Seok Choi, Soomin Jo, Joeun Kim, Jae Yoon Park, Seung Eun Lee · 2026 · Journal of Diabetes Investigation
  37. Back off to better blow up: acute GFR decrease at SGLT-2 inhibitor initiation
    Maurice Laville · 2021 · Kidney International
  38. What Have We Learned so Far From the Use of Sodium-Glucose Cotransporter 2 Inhibitors in Clinical Practice?
    Peter R Rossing, Frederik Persson · 2021 · Advances in Chronic Kidney Disease
  39. Comment on Lee et al. Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score–Matched Cohort Study. Diabetes Care 2021;44:2419–2426
    Sylvie Feldman-Billard, Michel Pâques · 2022 · Diabetes Care
  40. Navigating the Drop in Estimated GFR That We See With Drugs That Modify Cardiorenal Events
    Matthew R. Weir · 2025 · Mayo Clinic Proceedings
  41. Les inhibiteurs du cotransporteur du sodium-glucose de type 2 pour l’insuffisance cardiaque avec fraction d’éjection réduite
    Jamie Falk, Jennifer Potter, Ricky D. Turgeon · 2021 · Canadian Family Physician
  42. Efeito dos inibidores do co-transportador sódio-glicose tipo 2 sobre o desfecho renal: Uma revisão integrativa
    Cristiene Neta de Sá Araújo, Letícia Macêdo de Oliveira, Yasmim Campos Rodrigues, Luciane de Jesus Mendes Santos, Rafaella Lopes Ferreira, Willyanna Ravanielly Oliveira de Carvalho, Even Kaline Varella Jardim · 2023 · Research Society and Development
  43. Improving kidney protection in patients with type 2 diabetes
    Annemarie B. van der Aart‐van der Beek · 2023 · University of Groningen research database (University of Groningen / Centre for Information Technology)
  44. Knowledge, Attitude and Practice in Managing Chronic Kidney Disease with SGLT2 Inhibitors
    Bipin Kumar Sethi, Chethan Dev K, Praveen Kumar Ns, A Thamburaj, Ashish Birla, Ashish Prasad · 2023 · Asian Journal of Diabetology
  45. Best Practices in the Use of Sodium–Glucose Cotransporter 2 Inhibitors in Diabetes and Chronic Kidney Disease for Primary Care
    Jay H. Shubrook, Joshua J. Neumiller, Radica Z. Alicic, Tom Manley, Katherine R. Tuttle · 2023 · Diabetology
  46. Diabetische Nephropathie 2023 – Beginn eines neuen Zeitalters
    Tom H. Lindner, Werner Alfons Scherbaum · 2024 · Die Diabetologie
  47. Managing Heart Failure in Chronic Kidney Disease: A Review of Current Literature
    Benjamin Lidgard, Nisha Bansal · 2024 · Current Treatment Options in Cardiovascular Medicine
  48. Chronische Niereninsuffizienz bei Typ-2-Diabetes – die stille Bedrohung einer Multisystemerkrankung
    Merve Günes-Altan, Roland Erich Schmieder · 2024 · Aktuelle Kardiologie
  49. Uma análise dos benefícios dos Inibidores do SGLT2 na evolução da doença renal crônica além do diabetes mellitus tipo 2
    Luanna Sousa Borges Silva, Tallita Lougon Duarte, Isabella Harume Ribeiro Hojo, Larissa de Oliveira Lima Fonseca · 2024 · Revista Eletrônica Acervo Médico
  50. Estimated glomerular filtration rate dip at sodium-glucose cotransporter 2 inhibitor initiation: Implications for practice in chronic kidney disease
    Ying Fan, Niansong Wang · 2024 · Chinese Medical Journal
  51. Systolic blood pressure is associated with early and long-term changes in renal function in patients with dapagliflozin-treated moderate-to-advanced chronic kidney disease
    Katsunori Yanai, Keiji Hirai, Taisuke Kitano, Haruhisa Miyazawa, Kiyonori Ito, Susumu Ookawara, Yoshiyuki Morishita · 2025 · Clinical and Experimental Nephrology
  52. Leitliniengerechte Therapie der chronischen Nierenerkrankung
    Lea Weiland · 2025 · Info Diabetologie
  53. In Reply: eGFR Decline at Initiation of Sodium-Glucose Cotransporter 2 Inhibitors
    Chi‐Yu Chen, Shao‐Sung Huang, Der‐Cherng Tarng, Wei‐Cheng Tseng · 2025 · Mayo Clinic Proceedings
  54. Impact of SGLT2 Inhibitors on Glomerular Filtration in Type 1 Diabetes
    Michael W. Holliday, Sankar Dass Navaneethan · 2025 · The Journal of Clinical Endocrinology & Metabolism
  55. Chronische Niereninsuffizienz bei Typ-2-Diabetes – die stille Bedrohung einer Multisystemerkrankung
    Merve Günes-Altan, Roland Schmieder · 2025 · Diabetes aktuell
  56. Role of Sodium-Glucose Transport Protein-2 Inhibitors in Renal Protection: A Narrative Review from the Cardiovascular-Kidney-Metabolic Interconnection
    Nan Ye, Hong Cheng · 2026 · Drug Design Development and Therapy
  57. Real-world longitudinal trends in glycaemic control, renal function, and lipid profiles among Malaysian patients receiving sodium–glucose cotransporter 2 inhibitors
    Abdullah Faiz Zaihan, Nurul Ameera Huda Mohamad Hafiz, Nur Irdina Athilah Khairul Hazamy, Aisyah Zahraa Termizy, Nurul Izzah Roslan, Perishithaa M Ganesan, Sze Hwe Choe, Chia Siang Kow · 2026 · Asian Heart Journal
  58. Implications of acute change in estimated Glomerular Filtration Rate (eGFR) for the effect of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on long-term endpoints
    Ransmond O. Berchie, Lesley A. Inker, Hiddo J.L. Heerspink, Ben Haaland, Tom Greene · 2026 · PLoS ONE
  59. Protocol for Developing and Validating a Multimarker-Clinical Prediction Model of SGLT2 Inhibitor-Induced Acute eGFR Dip in CKD Stages 3–4: A Three-Stage Urinary Proteomics Study
    Zhi-Yu Duan, Gao Y, Mengjie Huang, Yanjun Liang, Jing Hao, Jie Wang, Guangyan Cai · 2026 · Life
  60. Acute Estimated Glomerular Filtration Rate Changes With Guideline Directed Medical Therapy Initiation in Heart Failure
    Ankit Mehta · 2026 · The American Journal of Cardiology
  61. Efficacy and safety of finerenone with or without combination therapy in patients with non-diabetic chronic kidney disease: a real-world observational study
    Yanli Fang, Yun Shao, Xinyi Lin, Qihui Xu, 尚玉, Mingli Chen, Siyi Chen, Yinqiu Lv, Jianna Zhang, Huidi Zhang · 2026 · Journal of Nephrology
  62. Time‐Dependent Accrual of Cardiorenal Benefit With SGLT2 Inhibitors in Chronic Kidney Disease: A Reconstructed Individual Patient Data Meta‐Analysis of Randomized Trials
    Shotaro Yoshida, Mashiro Iwatsubo, Takahiro Nakamura, 牧子 小田, Yusuke Sakamaki · 2026 · Diabetes Obesity and Metabolism
  63. Temporal distribution of acute kidney injury–related hospitalizations after initiation of sodium–glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single‐center eGFR analysis
    Kazuya Hiura, Ayana Tatsuno, Yamato Noto, RYOSUKE WAKAMATSU, Masayuki Sakunami, Ryu Kobayashi, Miki Yamashita · 2026 · Journal of Diabetes Investigation
  64. SGLT2 Inhibitors as Potential Agents for Prevention, Treatment, and/or Improved Recovery from Acute Kidney Injury
    Dianet Sanchez Vega, Ellen Oskoui, Leah J. Siskind · 2026 · Handbook of experimental pharmacology
  65. The eGFR dip after SGLT2 inhibition: when worsening kidney function does not mean kidney injury
    Charlotte Delrue, Marijn M. Speeckaert · 2026 · Acta Clinica Belgica
  66. Early Relative eGFR Decline After SGLT2 Inhibitor Initiation in Heart Failure: Clinical Correlates and Pretreatment-Anchored 12-Month Trajectories
    Yoriyasu Suzuki, Tomohiro Onishi, Yusuke Nakano, Masahiro Shimoda, Reiji Goto, Takahiko Suzuki, Tetsuya Amano · 2026 · Journal of Clinical Medicine
  67. Effects of sodium-glucose cotransporter 2 inhibitors on the kidneys: a pharmacovigilance study and genetic causal analysis
    Zhiwang Lai, Huan Ye, Jiayuan Lai, Junyao Lin, Hongjin Gao · 2026 · The Egyptian Journal of Internal Medicine